The Pfizer/BioNTech vaccine for COVID-19 has reached the end of clinical trials and is now being rolled out in multiple countries. Regulatory bodies in the UK, Canada and the US have granted temporary or emergency use authorization for the vaccine to be given to the public.
This is a landmark moment. Building a biological barrier against the virus is now a possibility. A highly effective vaccine, used in combination with current physical barriers, raises hope that bringing an end to the pandemic is achievable.
And after the tantalizing interim results released by Pfizer last month, we can now see the full peer-reviewed results of its phase 3 trial. Here’s what they tell us.
